The effect of 5‐azacytidine treatment delays and dose reductions on the prognosis of patients with myelodysplastic syndrome: how to optimize treatment results and outcomes-Reference-Cited by-同舟云学术

The effect of 5‐azacytidine treatment delays and dose reductions on the prognosis of patients with myelodysplastic syndrome: how to optimize treatment results and outcomes

Published:2020-08-30 Issue:6 Volume:192 Page:978-987
ISSN:0007-1048
Container-title:British Journal of Haematology
language:en
Short-container-title:Br J Haematol

Author:

Diamantopoulos Panagiotis T.¹^ORCID,Symeonidis Argiris²,Pappa Vasiliki³,Kotsianidis Ioannis⁴,Galanopoulos Athanasios⁵,Pontikoglou Charalampos⁶,Anagnostopoulos Achilles⁷,Vassilopoulos George⁸,Zikos Panagiotis⁹,Hatzimichael Eleftheria¹⁰,Papaioannou Maria¹¹,Megalakaki Aekaterini¹²,Repousis Panagiotis¹²,Kotsopoulou Maria¹²,Dimou Maria¹³,Solomou Elena²,Dryllis Georgios¹,Tsokanas Dimitrios⁵,Papoutselis Menelaos‐Konstantinos⁴,Papageorgiou Sotirios³^ORCID,Kyrtshonis Marie‐Christine¹³,Kourakli Alexandra²,Papadaki Helen⁶^ORCID,Panayiotidis Panayiotis¹³,Viniou Nora‐Athina¹

Affiliation:

1. Hematology Unit First Department of Internal Medicine Laikon General HospitalNational and Kapodistrian University of Athens AthensGreece

2. Department of Internal Medicine University Hospital of Patras RioGreece

3. Haematology Division Second Department of Internal Medicine Attikon General HospitalNational and Kapodistrian University of Athens AthensGreece

4. Department of Hematology University Hospital of Alexandroupolis AlexandroupoliGreece

5. Department of Clinical Hematology 'G. Gennimatas' District General Hospital AthensGreece

6. Haematology Laboratory School of Medicine University of Crete HeraklionGreece

7. Hematology Department General Hospital of Thessaloniki “George Papanikolaou” Pilea ChortiatisGreece

8. Department of Hematology Larissa University HospitalUniversity of Thessalia LarissaGreece

9. Department of Hematology St Andrew' General Hospital PatrasGreece

10. Department of Haematology University of Ioannina IoanninaGreece

11. Hematology Department University General Hospital of Thessaloniki AHEPA ThessalonikiGreece

12. Department of Hematology Metaxa Anticancer Hospital PiraeusGreece

13. First Propedeutic Department of Internal Medicine School of Medicine National and Kapodistrian University of Athens Athens Greece

Funder

Genesis Pharma

Publisher

Wiley

Subject

Hematology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/bjh.17062

Reference16 articles.

1. Medicines.org.uk.Vidaza 25 Mg/Ml Powder For Suspension For Injection ‐ Summary Of Product Characteristics (Smpc) ‐ (Emc).2020. Available athttps://www.medicines.org.uk/emc/product/6468/smpc[Accessed 2 May 2020].

2. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study

3. Randomized Controlled Trial of Azacitidine in Patients With the Myelodysplastic Syndrome: A Study of the Cancer and Leukemia Group B

4. Five-day regimen of azacitidine for lower-risk myelodysplastic syndromes (refractory anemia or refractory anemia with ringed sideroblasts): A prospective single-arm phase 2 trial

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Clinical impacts of severe thrombocytopenia in the first cycle of azacitidine monotherapy and cytogenetics in patients with myelodysplastic syndrome: The Kyoto Conditional Survival Scoring System;Oncology Letters;2023-12-18

2. Mutational Profile Enables the Identification of a High-Risk Subgroup in Myelodysplastic Syndromes with Isolated Trisomy 8;Cancers;2023-07-27

3. MUTATIONAL PROFILE ENABLES THE IDENTIFICATION OF A HIGH RISK SUBGROUP IN MYELODYSPLASTIC SYNDROMES WITH ISOLATED TRISOMY 8;2023-01-20

4. Epigenetic regulation of macrophage polarization in wound healing;Burns & Trauma;2023-01-01

5. Comorbidities and frailty predict outcome of patients with myelodysplastic syndromes. Should we integrate them in novel prognostic scoring systems?;Journal of Geriatric Oncology;2021-09